API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LOU064 (remibrutinib) is a highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor, being investigated in a late stage study for spontaneous urticaria.
Lead Product(s): Remibrutinib
Therapeutic Area: Immunology Product Name: LOU064
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Details:
LOU064 (remibrutinib) is a highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor that blocks the BTK cascade and prevents the release of histamine that causes itch, hives/welts and swelling, which is investigated for spontaneous urticaria.
Lead Product(s): Remibrutinib
Therapeutic Area: Immunology Product Name: LOU064
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
LOU064 (remibrutinib) is a highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor that blocks the BTK cascade and prevents the release of histamine that causes itch, hives/welts and swelling.
Lead Product(s): Remibrutinib
Therapeutic Area: Immunology Product Name: LOU064
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
Remibrutinib is a highly selective, potent oral BTK inhibitor discovered within Novartis and being developed in a number of clinical and early settings. The primary endpoint was achieved with remibrutinib showing a significant dose-response compared to placebo.
Lead Product(s): Remibrutinib
Therapeutic Area: Immunology Product Name: LOU064
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021